The NSRX analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month price target is $22.00, representing +656.01% upside from the current price of $2.91.

Competitors & Peers

#TickerCompanyPriceChangeMkt Cap

NSRX

Nasus Pharma Ltd.

Acrivon Therapeutics, Inc. Common Stock

$1.41+2.84%$44.5M #4

ADAG

Adagene Inc.

$3.26-1.81%$122.7M #5

Fortress Biotech, Inc.

$2.85+2.46%$94.7M

Stock Performance

Full History

1D+3.09%

1W-4.77%

1M-4.77%

3M-27.01%

YTD-67.21%

1Y-63.64%

5Y-63.64%

About Nasus Pharma Ltd.

CEODan Teleman

IPO DateAug 13, 2025

Employees2

CountryIL

Websitenasuspharma.com

Nasus Pharma Ltd. is a specialized pharmaceutical firm currently advancing through clinical trials. Their primary focus is on developing innovative nasal medications designed to swiftly address critic…

Biotechnology HealthcareAMEXIL

About Stock Overview & Key Data

Nasus Pharma Ltd. (NSRX) is a Healthcare company in the Biotechnology industry, listed on AMEX since Aug 13, 2025. As of the latest trading session, NSRX stock price is $2.91, with a market capitalization of $25.8M. The stock has returned -63.64% over the past 12 months and -67.21% year-to-date.

According to 1 Wall Street analysts, the consensus rating for Nasus Pharma Ltd. stock is Buy, with an average 12-month price target of $22.00. In fiscal year 2024, Nasus Pharma Ltd. reported revenue of — and net income of -$1.5M. For detailed data — including Nasus Pharma Ltd. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Nasus Pharma Ltd. (NSRX) stock price is $2.91. The stock is traded on AMEX under the ticker symbol NSRX. The 52-week range is $1.98 – $9.99.

NSRX stock priceNSRX quote todaylive ticker

Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice